RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.

Jordan L KohlmeyerCourtney A KaemmerCasey PulliamChandra K MaharjanAllison Moreno SamayoaHeather J MajorKendall E CornickVickie Knepper-AdrianRajesh KhannaJessica C SierenMariah R LeidingerDavid K MeyerholzK D ZambaJill M WeimerRebecca D DoddBenjamin W DarbroMunir R TanasDawn E Quelle

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

RABL6A is a new driver of MPNST pathogenesis that acts in part through p27-RB1 inactivation. Our results suggest RB1 targeted therapy with multiple pathway drugs may effectively treat MPNSTs.

Keyphrases

drug induced